Neoadjuvant HER2+

>

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Latest News

Antonio Llombart-Cussac, MD, PhD
Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

May 1st 2024

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

ERBB2/HER2-positive early breast cancer
Tumor Intrinsic Subtype Affects Relationship Between pCR and EFS in ERBB2+/HER2+ Early Breast Cancer

April 30th 2024

MRI-guided treatment for duration of neoadjuvant chemotherapy in hormone receptor-negative HER2-positive breast cancer
MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer

April 28th 2024

Breast Cancer | adobe.stock.com
Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer

April 16th 2024

Aiham Qdaisat, MD, of MD Anderson Cancer Center
Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer

April 9th 2024

<1
...